32results about "Phosphorus-oxygen lyases" patented technology

Provided herein are methods for producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

The invention discloses a recombinant salmonella choleraesuis nuclease regulation vector as well as a construction method and application thereof. After oral administration, the recombinant salmonella choleraesuis nuclease regulatory vector rSC0140 enters host immune cells, c-di-AMP is released, a host STING pathway is activated, and a broad-spectrum antiviral effect can be achieved; the recombinant strain rSC0140 is proved to be capable of activating STING pathways in macrophages and mice, causing antiviral states of the macrophages and the mice and resisting challenge of various influenza viruses; the recombinant strain has broad-spectrum antiviral efficacy and is suitable for preventing and treating various virus diseases clinically.

The invention provides a pseudomonas aeruginosa engineering bacterium which is based on a PAO1 wild type strain, and two of the following genes, namely cyaA and cyaB, are knocked out from a genome at the same time. According to the pseudomonas aeruginosa engineering bacterium, the cyaA gene and the cyaB gene are knocked out at the same time, and the yield of rhamnolipid is remarkably increased on the premise that existing PAO1 fermentation process parameters and processes are not changed. The yield cannot be increased when the cyaA or the cyaB is singly knocked out, and the synergistic effect of double-gene knockout is proved.

Disclosed herein are nucleic acid constructs that can be used to build genetic circuits for producing antibodies comprising split toxins. Also disclosed herein are methods of producing platelets comprising the antibodies. The platelets produced by the methods disclosed herein can be used to target circulating tumor cells.

The present disclosure describes compositions and methods of treating solid tumors using chimeric antigen receptor (CAR) T cell (CAR-T) therapy and / or antibodies targeting uanylate Cyclase 2C (GCC. GUCY2C). The compositions include CAR comprising an extracellular domain that binds GCC. Further disclosed are methods of using modified T ceils expressing a CAR that binds GCC for treating different types of carters.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

This disclosure relates to methods for increasing plant immunity or resistance to plant pathogens or pests, or inhibiting plant pathogens or pests, by supplying antimicrobial or antifungal oligopeptides. Antimicrobial or antifungal oligopeptides and nucleic acids encoding said oligopeptides are also provided herein. Compositions, kits, and cells comprising antimicrobial or antifungal oligopeptides are also provided.

Methods and materials for treating chronic cardiac disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) to treat hypertrophic cardiomyopathy and other cardiac conditions, such as conditions associated with ventricular hypertrophy, atrial hypertrophy, ventricular remodeling, atrial remodeling, systolic and / or diastolic dysfunction, heart failure (e.g., heart failure with reduced ejection fraction, heart failure with mildly reduced ejection fraction, and heart failure with preserved ejection fraction), and other forms of chronic heart disease (e.g., Fabry disease, Noonan syndrome, Pompe disease, PRKAG2-related cardiomyopathy, Danon disease, Friedrich ataxia cardiomyopathy, amyloidosis, or desminopathy) are provided herein.

Disclosed herein are methods that provide optimal conditions for site-specific digestion and mapping of the sequence of RNA polynucleotides using T2 family endoribonucleases, such as RNase MCI and Cusativin.

The present disclosure relates to methods of increasing plant immunity or resistance to plant pathogens or pests in a plant, or inhibiting a plant pathogen or pest by providing an antimicrobial or antifungal oligopeptide. Also provided herein are antimicrobial or antifungal oligopeptides, and nucleic acids encoding said oligopeptides. Also provided herein are compositions, kits and cells comprising antimicrobial or antifungal oligopeptides.

Disclosed are viral vector compositions comprising polynucleotide sequences that express one or more biologically-active mammalian guanylate cyclase proteins. Also disclosed are methods for their use in preventing, treating, and / or ameliorating at least one or more symptoms of a disease, disorder, abnormal condition, or dysfunction resulting at least in part from a guanylate cyclase deficiency in vivo. In particular embodiments, the use of recombinant adeno-associated viral (rAAV) vectors to treat or ameliorate symptoms of Leber's congenital amaurosis, as well as other conditions caused by an absence or reduction in the expression of a functional retinal-specific guanylate cyclase 1 (retGC1).

Disclosed herein are methods that provide optimal conditions for site-specific digestion and mapping of the sequence of RNA polynucleotides using T2 family endoribonucleases, such as RNase MC1 and Cusativin.

Methods and materials for treating skeletal disorders are provided herein. For example, methods and materials for using a dual guanylate cyclase A and B activator (e.g., a polypeptide having the sequence set forth in SEQ ID NO:1) as a therapeutic agent for the treatment of skeletal disorders (e.g., achondroplasia) are provided herein.

Provided is a GUCY2C T cell antigen coupler (TAC) polypeptide having (i) an antigen binding domain (e.g., a nanobody) that binds GUCY2C, (ii) an antigen binding domain that binds a protein associated with the TCR complex, and (iii) a T cell receptor signaling domain polypeptide.

Provided are an antigen-binding molecule specifically binding to GUCY2C and CD3 and pharmaceutical use thereof. The antigen-binding molecule can be used for treating tumor.

Increased space-time yield, carbon conversion efficiency, and carbon substrate flexibility in fine chemical production. The present inventors have found that increasing cAMP levels and / or manipulating the PTS system can have a surprising positive effect on the space-time yield, carbon conversion efficiency, and carbon substrate flexibility of fine chemical production in the host organism. This was achieved by deregulating adenylate cyclase cyaa through deletion of the C-terminal regulatory region, which leads to increased cAMP levels, or by deleting the Crr protein activity that regulates the carbohydrate utilization system (carbohydrate repression resistance). Both resulted in increased production of 2-fucosyllactose and 6-sialyllactose (human milk oligosaccharides), enhancing carbohydrate utilization.

A protein according to one embodiment of the present invention has a photoactivated adenylyl cyclase activity, and consists of the amino acid sequence of SEQ ID No. 1 with 1-18 amino acid residues deleted from the C-terminus, or an amino acid sequence having 90% or more sequence identity therewith. According to the present invention, a novel photoactivated adenylyl cyclase having a higher photoactivation efficiency compared to a wild-type OaPAC protein can be provided.

An immune-cell-targeting antibody or a functional fragment thereof, and an application thereof. The antibody or the functional fragment thereof targets and identifies a Triokinase / FMN cyclase C-terminus fragment sequence. The antibody can be directly used for tagging and identifying immune cells. After the antibody and an antigen polypeptide thereof combine to form a self-assembled complex, the immune cell identification effect thereof is significantly improved, and in related applications can exhibit a decreased lower detection limit, thereby greatly improving identification capabilities and detection sensitivity for various immune cells. Moreover, a probe obtained on the basis of the antibody can likewise carry various modification groups and reporter groups, and can thus be used in approaches to different application scenarios, such as flow cytometry, immunofluorescence imaging, immunoassays, detection chips, etc., and has flexible and broad applicability and scope of application.

Provided herein are methods of producing peptides from inclusion bodies. Also provided herein are onconase variants with improved properties.

Disclosed are methods of decreasing serum low density lipoprotein (LDL) level in a subject. The methods include inhibiting expression or function of an adenylate cyclase in the subject, wherein the inhibiting includes administration of an inhibitory nucleic acid molecule, such as an siRNA, to the subject.

The invention discloses an AC (at) Mg / Ce-UiO nano particle, a preparation method thereof and application of the nano particle in medicines for treating inflammatory dermatosis, and belongs to the technical field of biological medicines. Adenylate cyclase (AC) is encapsulated in situ in an Mg / Ce-UiO metal organic framework designed by defect engineering, and a unique structure brings dual treatment strategies: the encapsulated AC catalyzes pro-inflammatory ATP to be converted into anti-inflammatory cAMP to restore balance; defective Mg / Ce-UiO simulates SOD (superoxide dismutase) and CAT (catalase) to remove excessive ROS. The nanoparticles can down-regulate the expression of various inflammatory factors and pruritus mediators, inhibit the excessive proliferation of keratinocytes and reduce the infiltration of immune memory T cells. Therefore, the effects of treating inflammatory skin disease skin lesion, remarkably relieving itching and preventing relapse are achieved. The preparation method is simple and easy for large-scale production. The invention introduces a reform mode to the treatment of inflammatory dermatosis, provides a curative strategy, establishes a multifunctional treatment framework, and is expected to be suitable for more extensive inflammation and autoimmune diseases.

Provided are anti-GCC single domain antibodies (e.g., VHH domain antibodies), and chimeric antigen receptors (CARs) that bind to GCC comprising same in an extracellular antigen binding domain, a transmembrane domain, and an intracellular signaling domain. Immune cells transduced with the disclosed CAR constructs and / or a chimeric receptor can be used for cancer immunotherapy.

A fusion protein is provided that simultaneously blocks the calcitonin gene-related peptide (CGRP) pathway and the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway, and the fusion protein comprises at least one single-domain antibody, at least one Fc fragment, and at least one extracellular domain fragment of pituitary adenylate cyclase 1 (PAC1 ECD). The fusion protein simultaneously blocks the CGRP and PACAP pathways, thereby improving the response rate of drugs for the treatment of migraine.

The present invention relates to micropeptides (miPEPs) and their use for enhancing plant immunity and increasing resistance to pathogens and pests. Also provided herein are kits comprising miPEPs.

Compartmentalization of cAMP signaling in reactive astrocytes is shown to promote neuroprotective astrocyte proliferation and neuronal survival for therapeutic applications.

The invention relates to the field of genetic engineering and biological catalysis, in particular to an adenylate cyclase mutant and application thereof in catalytic synthesis of cyclic adenosine monophosphate. The amino acid sequence of the mutant is obtained by mutating one or more of asparagine at the 76th site, methionine at the 119th site and valine at the 247th site in the sequence shown as SEQ ID NO.1. The invention further discloses a preparation method of the mutant. The enzyme activity of the mutant M119C at the optimum temperature of 40 DEG C is improved by 21.34% compared with that of wild type ArAC (the optimum temperature of 35 DEG C). And in the aspect of thermal stability, the half-life periods of the three mutants under different temperature conditions are obviously longer than those of a wild type, and the thermal stability of the enzyme is effectively improved. Meanwhile, the substrate affinity of the mutant M119C is enhanced compared with that of the wild type ArAC, and the catalytic efficiency of the mutant M119C is 2.43 times that of the wild type ArAC. In the application of catalytic synthesis of cyclic adenosine monophosphate by using the mutant M119C, the total yield of cyclic adenosine monophosphate is obviously increased by 22.94% compared with that of a wild type. The adenylate cyclase mutant disclosed by the invention provides a new scheme for industrial production of cyclic adenosine monophosphate.

The present invention relates to a recombinant protein comprising one or more fragments of pneumococcal surface protein A (PspA) and the adenylate cyclase (CyaA) from Bordetella species, especially Bordetella pertussis, wherein said PspA fragments are selected from clades 1 to 4, or a combination of two or more thereof. Additionally, the invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, especially a DNA sequence selected from the group consisting of nucleotide sequences as set forth in SEQ ID NOs: 12 to 18 and degenerate sequences thereof that encode a recombinant protein as set forth in SEQ ID NOs: 5 to 11 respectively. Further, an immunogenic composition comprising said recombinant protein or said expression cassette, and additionally a pharmaceutically acceptable carrier and / or adjuvant is disclosed. Finally, the invention relates to the use of said recombinant protein, or said expression cassette, or said immunogenic composition for the manufacture of a vaccine for preventing infections caused by Streptococcus pneumoniae, wherein said vaccine offers broad-spectrum protection against different pneumococcal isolates, regardless of serotypes.

GUCY2C T cell antigen coupler (TAC) polypeptides having (i) an antigen-binding domain that binds GUCY2C, (ii) an antigen-binding domain that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide are provided.